We provide venture, private equity or debt finance to regional businesses with growth ambition.
Providing the best possible support to our portfolio businesses and partners.
Striving to be the first choice for our investors, investees and colleagues.
The dedicated home of Mercia’s exclusive portfolio interviews, deep-dive blogs, insightful podcasts and educational webinars; all delivered by business leaders and industry experts.
Discover more about our Group including our approach to corporate governance and driving shareholder value
Business Description
Medherant is a developer of transdermal drug-in-adhesive patches using a novel adhesive exclusively licensed from Bostik, targeting central nervous system and pain indications.
Rationale for Investment
Building a leader in transdermal drug formulation and delivery, developing and out-licensing its own products as well as products of external partners seeking transdermal solutions.
Ken Cunningham – Non-executive Chair
John Burt – CEO
© 2022 Mercia Asset ManagementWebsite by 438